Electra Therapeutics: OrbiMed funds buy 473K shares
The shares are held by two funds, while the reporting entities disclaim beneficial ownership except to the extent of any pecuniary interest.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Electra Therapeutics, Inc. (ETRA) reported purchases of its common stock held directly by OrbiMed Private Investments VII, LP and OrbiMed Genesis Master Fund, L.P. The 10 transactions totaled 472,571 shares from November 3 through November 5, 2026, at reported prices of $7.07, $7.31, $7.78, $7.84 and $7.88 per share. No Rule 10b5-1 plan is reported. OrbiMed Advisors LLC, OrbiMed Capital GP VII LLC and OrbiMed Genesis GP LLC filed jointly and disclaim beneficial ownership except to the extent of any pecuniary interest.
Insider Trade Summary
Net Buyer: 472,571 shares
Net Buy
10 txns
Insider
ORBIMED ADVISORS LLC, OrbiMed Capital GP VII LLC, OrbiMed Genesis GP LLC
Role
Director, 10% Owner | Director, 10% Owner | Director, 10% Owner
Bought
472,571 shs ($3.61M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock F1, F3 | 30,891 | $7.31 | $226K |
| Purchase | Common Stock F2, F3 | 125,200 | $7.31 | $915K |
| Purchase | Common Stock F1, F3 | 9,267 | $7.78 | $72K |
| Purchase | Common Stock F2, F3 | 37,100 | $7.78 | $289K |
| Purchase | Common Stock F1, F3 | 5,000 | $7.07 | $35K |
| Purchase | Common Stock F2, F3 | 20,000 | $7.07 | $141K |
| Purchase | Common Stock F1, F3 | 24,313 | $7.84 | $191K |
| Purchase | Common Stock F2, F3 | 97,800 | $7.84 | $767K |
| Purchase | Common Stock F1, F3 | 24,400 | $7.88 | $192K |
| Purchase | Common Stock F2, F3 | 98,600 | $7.88 | $777K |
Holdings After Transaction:
Common Stock — 2,136,979 shares (Indirect, See footnotes)
Footnotes (3)
- F1. These securities are held directly by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII. OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI VII.
- F2. These securities are held directly by OrbiMed Genesis Master Fund, L.P. ("OrbiMed Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of OrbiMed Genesis. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OrbiMed Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OrbiMed Genesis.
- F3. This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.
Key Figures
Common shares purchased: 472,571 shares
Purchase price per share: $7.07
Purchase price per share: $7.31
+3 more
6 metrics
Common shares purchased
472,571 shares
Total across 10 reported purchases
Purchase price per share
$7.07
Purchases on November 4, 2026
Purchase price per share
$7.31
Purchases on November 5, 2026
Purchase price per share
$7.78
Purchases on November 4, 2026
Purchase price per share
$7.84
Purchases on November 3, 2026
Purchase price per share
$7.88
Purchases on November 3, 2026
Key Terms
beneficial ownership, pecuniary interest, voting power, general partner
4 terms
beneficial ownership regulatory
"may be deemed to have beneficial ownership over such securities"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
pecuniary interest regulatory
"except to the extent of its pecuniary interest therein, if any"
voting power regulatory
"may be deemed to have voting power and investment power"
Voting power is the ability shareholders have to influence a company's major decisions—like electing the board, approving mergers, or changing corporate rules—based on the voting rights attached to the shares they hold. For investors it matters because greater voting power is like holding more keys to a building: it gives you a stronger say over management choices and the company’s strategy, which can affect future value and risk.
general partner technical
"is the general partner of OPI VII"
A general partner is the person or firm that runs an investment partnership and legally represents it — they make the day-to-day decisions, choose which assets to buy or sell, and are responsible for the partnership’s obligations. Investors care because the general partner’s judgment, risk-taking and fee and profit-sharing arrangements determine both the potential returns and the level of exposure to losses; think of the GP as the ship’s captain whose skill and honesty shape the voyage’s outcome.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.
